Get the Stockscreener App
74.96
16.89%
-15.23
After Hours:
75.10
0.14
+0.19%
Arcellx Inc stock is traded at $74.96, with a volume of 4.62M.
It is down -16.89% in the last 24 hours and down -11.48% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$90.19
Open:
$90.25
24h Volume:
4.62M
Relative Volume:
7.78
Market Cap:
$4.33B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-25.07
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
-17.02%
1M Performance:
-11.48%
6M Performance:
+17.27%
1Y Performance:
-17.12%
1-Day Range:
$71.66
$92.70
1-Week Range:
$71.66
$92.91
52-Week Range:
$47.86
$96.39
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
74.96 | 5.22B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-16-25 | Initiated | Stifel | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma - Seeking Alpha
Guggenheim reiterates Buy rating on Arcellx stock, says weakness overdone - Investing.com India
Citi says Arcellx weakness on ‘highly preliminary’ Kelonia data an overreaction - TipRanks
Why Arcellx Inc Shares Took a Hit Today - TipRanks
Arcellx stock falls after Kelonia reveals promising blood cancer data By Investing.com - Investing.com Canada
Arcellx weakness on competitive worries ‘overdone,’ says Guggenheim - TipRanks
Can Arcellx Inc. stock withstand economic slowdownEarnings Beat & Proven Capital Preservation Methods - newser.com
Arcellx Inc’s Strategic Advantage in Gilead Partnership Drives Buy Rating and $130 Price Target - TipRanks
Risk vs reward if holding onto Arcellx Inc.Weekly Risk Report & Entry Point Confirmation Signals - newser.com
What institutional flow reveals about Arcellx Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Tools to assess Arcellx Inc.’s risk profileWeekly Stock Recap & Expert Verified Stock Movement Alerts - newser.com
How Arcellx Inc. stock performs during Fed tightening cyclesPrice Action & AI Forecasted Entry/Exit Points - newser.com
Is Arcellx Inc. stock a dividend growth opportunityQuarterly Trade Report & AI Driven Stock Movement Reports - newser.com
Why Arcellx Inc. is moving today2025 Price Targets & Daily Market Momentum Tracking - newser.com
Wolfe Research Initiates Coverage of Arcellx (ACLX) with Peer Perform Recommendation - Nasdaq
Arcellx (NASDAQ: ACLX) plans ASH event on Phase 2 iMMagine-1 myeloma trial data - Stock Titan
Arcellx CMO Heery sells $30,600 in ACLX stock By Investing.com - Investing.com South Africa
Arcellx CMO Heery sells $30,600 in ACLX stock - Investing.com India
Arcellx stock initiated at Peerperform by Wolfe Research amid BCMA market competition - Investing.com Nigeria
Arcellx initiated with a Peer Perform at Wolfe Research - TipRanks
Can technical indicators confirm Arcellx Inc.’s reversalGlobal Markets & High Return Stock Watch Alerts - newser.com
Will Arcellx Inc. stock split again soonJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Trend analysis for Arcellx Inc. this weekSwing Trade & Community Trade Idea Sharing - newser.com
Price-Driven Insight from (ACLX) for Rule-Based Strategy - news.stocktradersdaily.com
Using Python tools to backtest Arcellx Inc. strategiesWatch List & Stepwise Entry and Exit Trade Signals - newser.com
Arcellx Inc.: Promising Developments and Strategic Positioning Drive Buy Rating - TipRanks
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):